COMMUNIQUÉS West-GlobeNewswire

Reviva Announces FDA Alignment on Brilaroxazine Clinical Trials for NDA in Schizophrenia
15/04/2024
- FDA acceptance of 4-week global registrational Phase 3 RECOVER-2 study - - Two positive 4-week studies plus a 12-month long-term safety study have potential to support a New Drug Application (NDA) for brilaroxazine in [...]
The United States FDA Awards Orphan Drug Designation (ODD) to NM5072 for Treating Paroxysmal Nocturnal Hemoglobinuria (PNH)
15/04/2024
A Promising Treatment for PNH Patients The United States Food and Drug Administration (FDA) has awarded orphan drug designation (ODD) to NM5072 for the treatment of anemia in PNH patients. The ODD provides NM5072 with a [...]
TOMI Environmental Solutions to Attend Interphex 2024
15/04/2024
FREDERICK, Md., April 15, 2024 (GLOBE NEWSWIRE) -- TOMI Environmental Solutions, Inc.® (“TOMI”) (NASDAQ: TOMZ), a global company specializing in disinfection and decontamination solutions, announces attendance at [...]
IO Biotech Expands Senior Leadership Team to Progress Commercialization Readiness
15/04/2024
Marjan Shamsaei, PharmD, Newly Appointed as Senior Vice President, Commercial Development and Portfolio Lead Brings Deep Oncology Product Commercialization Expertise NEW YORK, April 15, 2024 (GLOBE NEWSWIRE) -- IO [...]
PetMeds® Announces Fiscal 2024 Third Quarter Financial Results and Completion of Financial Restatement
15/04/2024
Fiscal 2024 3Q Revenue of $65.3 million , an 11% increase compared to last year including PetCareRx results. AutoShip & Save and PetPlus Membership, 52% of total revenue, up from 42% at the same time last year. [...]
Organovo Announces Positive Phase 2 Results for FXR314 in Metabolic Dysfunction-Associated Steatohepatitis (MASH) Showing Both Reduction in Liver Fat Content and Strong Safety and Tolerability Compared to Placebo
15/04/2024
SAN DIEGO, April 15, 2024 (GLOBE NEWSWIRE) -- Organovo Holdings, Inc. (Nasdaq:ONVO), a clinical stage biotechnology company focused on developing novel treatment approaches based on demonstration of clinical promise in [...]
Reviva Reports Full Year 2023 Financial Results and Recent Business Highlights
15/04/2024
– RECOVER-1 Phase 3 global trial successfully met all primary and secondary endpoints with statistically significant reductions across all major symptom domains in schizophrenia – – Initiation of registrational RECOVER- [...]
Turning dreams into reality: 1970s-inspired Lachine Hospital Foundation Gala raises $182,830 net to support the modernization and expansion of the Lachine Hospital
15/04/2024
The Lachine Hospital Foundation’s signature gala raised $182,830 net, to support the Dream Big: Lachine Hospital campaign, an ongoing collaboration between the Lachine Hospital Foundation and the MUHC Foundation DORVAL [...]
Nos rêves deviennent réalité : le gala de la Fondation de l’Hôpital de Lachine, inspiré des années 1970, permet de recueillir 182 830 $ net, pour soutenir la modernisation et l’agrandissement de l’Hôpital de Lachine.
15/04/2024
Le gala signature de la Fondation de l’Hôpital de Lachine a permis de recueillir 182 830 $ net pour soutenir la campagne Osez rêver pour l’Hôpital de Lachine, une collaboration entre la Fondation de l’Hôpital de Lachine [...]
Pulmocide Announces Successful Results from the OPERA-S Study: a Phase 2 Safety Study with Inhaled Opelconazole
15/04/2024
Inhaled opelconazole observed to be generally well tolerated in this study as prophylaxis against pulmonary aspergillosis in lung transplant patients Discontinuations due to drug-related adverse events and drug-drug [...]
London Research & Pharmaceuticals presents the advancement of LRP-661, their oral cannabidiol sulphate drug candidate at the prestigious Epilepsy Therapies & Diagnostics Development (ETDD) XVII conference in Miami
15/04/2024
LONDON, Ontario, April 15, 2024 (GLOBE NEWSWIRE) -- London Research & Pharmaceuticals has recently publicized data about its lead compound LRP-661 or Cannabidiol sulphate (CBDS), highlighting its safety, efficacy, [...]
Corcept Completes Enrollment in Phase 2 DAZALS Trial in Patients With Amyotrophic Lateral Sclerosis (ALS)
15/04/2024
MENLO PARK, Calif., April 15, 2024 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic [...]
Spinogenix Announces U.S. FDA Approval of its Investigational New Drug Application for its Phase 2a Clinical Trial of SPG601 for Fragile X Syndrome
15/04/2024
SPG601 is a once-a-day pill that works by restoring synaptic function to address core symptoms of Fragile X Syndrome SAN DIEGO, April 15, 2024 (GLOBE NEWSWIRE) -- Spinogenix, Inc., a clinical-stage biopharmaceutical [...]
DAXOR CORPORATION TO EXHIBIT AT THE MEDAXIOM CARDIOVASCULAR TRANSFORUM CONFERENCE SPRING’24 TO ADVANCE AWARENESS AND FURTHER ADOPTION OF DAXOR’S BLOOD VOLUME DIAGNOSTIC (BVA-100™)
15/04/2024
The Premier Event for Cardiovascular Industry Leaders and Clinicians Oak Ridge, TN, April 15, 2024 (GLOBE NEWSWIRE) -- Daxor Corporation (Nasdaq: DXR), the global leader in blood volume measurement technology, announces [...]
Akari Therapeutics to Present PAS-Nomacopan Pre-Clinical Electroretinography (ERG) Data at ARVO 2024
15/04/2024
BOSTON and LONDON, April 15, 2024 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), a biotechnology company developing advanced therapies for autoimmune and inflammatory diseases, today announced the company [...]
REPEAT – MEDIA ADVISORY: Press conferences with patients who have been charged user fees of hundreds or even thousands of dollars at for-profit surgery clinics
15/04/2024
TORONTO and LONDON and WATERLOO and BRAMPTON, Ontario, April 15, 2024 (GLOBE NEWSWIRE) -- Patients are being threatened with extremely long wait times, denied vital procedure information, and coerced or manipulated into [...]
Amarin to Report First Quarter 2024 Financial Results and Host Conference Call on May 1, 2024
15/04/2024
DUBLIN, Ireland and BRIDGEWATER, N.J., April 15, 2024 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today announced that it will host a conference call with Patrick Holt, President & CEO, and members of [...]
Chiesi USA Appoints Richard Smith as Vice President and Business Unit Leader, U.S. AIR
15/04/2024
Richard Smith brings 25 years of expertise in building commercial excellence and partnering with the healthcare community across multiple therapeutic areas Chiesi USA remains steadfast in its preparations for the full- [...]
Extendicare Announces April 2024 Dividend of C$0.04 per Share
15/04/2024
MARKHAM, Ontario, April 15, 2024 (GLOBE NEWSWIRE) -- Extendicare Inc. (“Extendicare” or the “Company”) (TSX: EXE) announced that it has declared a cash dividend of C$0.04 per common share of the Company (the “Common [...]

Pages